SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/106980"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/106980" > Regulation of growt...

Regulation of growth hormone signaling by selective estrogen receptor modulators occurs through suppression of protein tyrosine phosphatases.

Leung, Kin-Chuen (författare)
Brce, Jesena (författare)
Doyle, Nathan (författare)
visa fler...
Lee, Heather J (författare)
Leong, Gary M (författare)
Sjögren, Klara, 1970 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för invärtesmedicin,Institute of Medicine, Department of Internal Medicine
Ho, Ken K Y (författare)
visa färre...
 (creator_code:org_t)
The Endocrine Society, 2007
2007
Engelska.
Ingår i: Endocrinology. - : The Endocrine Society. - 0013-7227 .- 1945-7170. ; 148:5, s. 2417-23
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Activation of the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 5 (STAT5) pathway by GH is terminated by the suppressors of cytokine signaling (SOCSs) and protein tyrosine phosphatases, Src homology 2 domain-containing protein tyrosine phosphatase (SHP)-1 and SHP-2. Based on our recent report that estrogen inhibits GH signaling by stimulating SOCS-2 expression, we investigated the effects of selective estrogen receptor modulators (SERMs) on GH signaling in human embryonic kidney (HEK293) and breast cancer (MDA-MB-231) cells expressing human GH receptor and estrogen receptor-alpha. 17beta-estradiol (E(2)) suppressed GH activation of a STAT5-responsive luciferase reporter and JAK2 phosphorylation in both cell models. 4-hydroxytamoxifen and raloxifene augmented these actions of GH in HEK293 cells but not breast cancer cells. SOCS-2 expression in both cell types was stimulated by E(2) but unaffected by SERMs. In HEK293 cells, SHP-1 was inhibited by raloxifene and 4-hydroxytamoxifen, whereas the latter additionally inhibited SHP-2. The phosphatases were unaffected by E(2). In breast cancer cells, phosphatase activity was not altered by SERMs or E(2). In summary, estrogen inhibited the JAK2/STAT5 signaling of GH and stimulated SOCS-2 expression in both HEK293 and breast cancer cells. By contrast, SERMs augmented GH signaling by reducing SHP activities in HEK293 cells and had no effect on both in breast cancer cells. We provide the first evidence for a novel mechanism regulating GH signaling, in which SERMs enhance GH activation of the JAK2/STAT5 pathway in a cell-type-dependent manner by attenuating protein tyrosine phosphatase activities.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)

Nyckelord

Breast Neoplasms
Cell Line
Tumor
Dactinomycin
pharmacology
Estrogen Antagonists
pharmacology
Estrogens
pharmacology
Human Growth Hormone
metabolism
Humans
Intracellular Signaling Peptides and Proteins
metabolism
Janus Kinase 2
metabolism
Kidney
cytology
Protein Synthesis Inhibitors
pharmacology
Protein Tyrosine Phosphatase
Non-Receptor Type 11
Protein Tyrosine Phosphatase
Non-Receptor Type 6
metabolism
Protein Tyrosine Phosphatases
metabolism
Raloxifene
pharmacology
Receptors
Estrogen
antagonists & inhibitors
metabolism
STAT5 Transcription Factor
metabolism
Signal Transduction
drug effects
physiology
Suppressor of Cytokine Signaling Proteins
metabolism
Tamoxifen
pharmacology

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy